Biotechnology / Medical Research
Repros Therapeutics Inc Announces That FDA Recommends Running Phase 2b Trial Of Proellex-V In Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
Repros Therapeutics Inc announced it has met with the FDA regarding the clinical development of Proellex-V, the vaginally administered product, in the treatment of uterine fibroids. The FDA recommended that a Phase 2b study should be conducted as a prelude to the Phase 3 program. During the meeting,...
Norda ASA Plans Delisting from Oslo Stock Exchange
Norda ASA announced that its Board has decided to submit to the Company's General Meeting on June 20, 2013 a proposal for applying to the Oslo Stock Exchange ASA (OSE) for the consent of delisting the Company's shares from OSE. The background for the Board's proposal is that the Company's shares no...
Stemline Therapeutics Inc Announces Closing Of $60 Million Public Offering Of Common Stock
Stemline Therapeutics Inc announced the closing of its previously announced underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $14.50 per share. The gross proceeds to Stemline from the public offering are $60 million, before underwriting discounts and...
Clavis Pharma ASA Appoints Interim Chairman and Acting CEO
Clavis Pharma ASA announced that its Board of Directors has appointed Martin Nes, a Board Member of the Company, as Interim Chairman of the Board of Directors. Mr. Nes replaces Anders P. Wiklund, who resigned from the Board of Directors effective May 21, 2013. The Board has also appointed Gunnar...
Expansion & New Markets
Markets
- Sectors
- U.S.
- Europe
- Asia
Sector Summary
| Energy |  -0.83% |
| Basic Materials |  +0.06% |
| Industrials | -0.28% |
| Cyclical Goods & Services | -0.31% |
| Non-Cyclical Goods & Services | -0.01% |
| Financials | -0.79% |
| Healthcare | +0.18% |
| Technology | -0.96% |
| Telecoms | -0.77% |
| Utilities | -1.06% |
| DOW | 15,307.17 | -80.41 |
-0.52% |
| S&P 500 | 1,655.35 | -13.81 |
-0.83% |
| NASDAQ | 3,463.30 | -38.82 |
-1.11% |
| TR US Index | 151.47 | +0.24 |
+0.16% |
Upcoming Events
No related earnings announcements are currently scheduled within the next 7 days.
Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
